IRIS Accounts Production v25.1.4.42 02137067 Board of Directors 1.12.23 30.11.24 30.11.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh021370672023-11-30021370672024-11-30021370672023-12-012024-11-30021370672022-11-30021370672022-12-012023-11-30021370672023-11-3002137067ns15:EnglandWales2023-12-012024-11-3002137067ns14:PoundSterling2023-12-012024-11-3002137067ns10:Director12023-12-012024-11-3002137067ns10:PrivateLimitedCompanyLtd2023-12-012024-11-3002137067ns10:SmallEntities2023-12-012024-11-3002137067ns10:AuditExemptWithAccountantsReport2023-12-012024-11-3002137067ns10:SmallCompaniesRegimeForDirectorsReport2023-12-012024-11-3002137067ns10:SmallCompaniesRegimeForAccounts2023-12-012024-11-3002137067ns10:FullAccounts2023-12-012024-11-3002137067ns10:Director22023-12-012024-11-3002137067ns10:Director32023-12-012024-11-3002137067ns10:Director42023-12-012024-11-3002137067ns10:RegisteredOffice2023-12-012024-11-3002137067ns5:CurrentFinancialInstruments2024-11-3002137067ns5:CurrentFinancialInstruments2023-11-3002137067ns5:Non-currentFinancialInstruments2024-11-3002137067ns5:Non-currentFinancialInstruments2023-11-3002137067ns5:ShareCapital2024-11-3002137067ns5:ShareCapital2023-11-3002137067ns5:RevaluationReserve2024-11-3002137067ns5:RevaluationReserve2023-11-3002137067ns5:RetainedEarningsAccumulatedLosses2024-11-3002137067ns5:RetainedEarningsAccumulatedLosses2023-11-3002137067ns5:PlantMachinery2023-11-3002137067ns5:PlantMachinery2023-12-012024-11-3002137067ns5:PlantMachinery2024-11-3002137067ns5:PlantMachinery2023-11-3002137067ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-3002137067ns5:WithinOneYearns5:CurrentFinancialInstruments2023-11-3002137067ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2024-11-3002137067ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2023-11-3002137067ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2024-11-3002137067ns5:BetweenOneFiveYearsns5:HirePurchaseContracts2023-11-3002137067ns5:HirePurchaseContracts2024-11-3002137067ns5:HirePurchaseContracts2023-11-3002137067ns5:WithinOneYear2024-11-3002137067ns5:WithinOneYear2023-11-3002137067ns5:BetweenOneFiveYears2024-11-3002137067ns5:BetweenOneFiveYears2023-11-3002137067ns5:AllPeriods2024-11-3002137067ns5:AllPeriods2023-11-3002137067ns5:Secured2024-11-3002137067ns5:Secured2023-11-3002137067ns5:RevaluationReserve2023-11-30
REGISTERED NUMBER: 02137067 (England and Wales)















Unaudited Financial Statements

for the Year Ended 30th November 2024

for

ESSEX INJECTION MOULDINGS
LIMITED

ESSEX INJECTION MOULDINGS
LIMITED (REGISTERED NUMBER: 02137067)

Contents of the Financial Statements
for the year ended 30th November 2024










Page

Company Information 1

Chartered Accountants' Report 2

Balance Sheet 3

Notes to the Financial Statements 5


ESSEX INJECTION MOULDINGS
LIMITED

Company Information
for the year ended 30th November 2024







DIRECTORS: Mr P S Measures
Mr J C King
Mr D M Leighton
Mr L Watkins





REGISTERED OFFICE: Monometer House
Rectory Grove
Leigh on Sea
Essex
SS9 2HL





REGISTERED NUMBER: 02137067 (England and Wales)





ACCOUNTANTS: Barrons Limited
Chartered Accountants
Monometer House
Rectory Grove
Leigh on Sea
Essex
SS9 2HN

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Essex Injection Mouldings
Limited


The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Profit and Loss Account and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Essex Injection Mouldings Limited for the year ended 30th November 2024 which comprise the Profit and Loss Account, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Essex Injection Mouldings Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Essex Injection Mouldings Limited and state those matters that we have agreed to state to the Board of Directors of Essex Injection Mouldings Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Essex Injection Mouldings Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Essex Injection Mouldings Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Essex Injection Mouldings Limited. You consider that Essex Injection Mouldings Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Essex Injection Mouldings Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Barrons Limited
Chartered Accountants
Monometer House
Rectory Grove
Leigh on Sea
Essex
SS9 2HN


19th August 2025

ESSEX INJECTION MOULDINGS
LIMITED (REGISTERED NUMBER: 02137067)

Balance Sheet
30th November 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 207,154 219,978

CURRENT ASSETS
Stocks 100,410 95,440
Debtors 5 664,586 751,260
Cash at bank and in hand 31,767 11,457
796,763 858,157
CREDITORS
Amounts falling due within one year 6 437,452 518,359
NET CURRENT ASSETS 359,311 339,798
TOTAL ASSETS LESS CURRENT
LIABILITIES

566,465

559,776

CREDITORS
Amounts falling due after more than one
year

7

(124,842

)

(171,776

)

PROVISIONS FOR LIABILITIES (35,552 ) (37,692 )
NET ASSETS 406,071 350,308

CAPITAL AND RESERVES
Called up share capital 1,000 1,000
Revaluation reserve 10 119,003 120,222
Retained earnings 286,068 229,086
SHAREHOLDERS' FUNDS 406,071 350,308

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30th November 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30th November 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

ESSEX INJECTION MOULDINGS
LIMITED (REGISTERED NUMBER: 02137067)

Balance Sheet - continued
30th November 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19th August 2025 and were signed on its behalf by:





Mr J C King - Director


ESSEX INJECTION MOULDINGS
LIMITED (REGISTERED NUMBER: 02137067)

Notes to the Financial Statements
for the year ended 30th November 2024


1. STATUTORY INFORMATION

Essex Injection Mouldings Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
The turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before the revenue is recognised:

Sale of goods
Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
- the Company has transferred the significant risks and rewards of ownership to the buyer;
- the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the transaction; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services
Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

Tangible fixed assets
Tangible fixed assets are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less residual value over their estimated useful lives, using either a straight line or reducing balance method, as indicated below.

Depreciation is provided on the following basis:

Plant and machinery- 15% on reducing balance
Fixtures and fittings- 15% on reducing balance
Motor vehicles- 20% on reducing balance
Computer equipment- 33% on reducing balance

The asset's residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

ESSEX INJECTION MOULDINGS
LIMITED (REGISTERED NUMBER: 02137067)

Notes to the Financial Statements - continued
for the year ended 30th November 2024


2. ACCOUNTING POLICIES - continued

Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If Stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit and loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

ESSEX INJECTION MOULDINGS
LIMITED (REGISTERED NUMBER: 02137067)

Notes to the Financial Statements - continued
for the year ended 30th November 2024


2. ACCOUNTING POLICIES - continued

Government grants
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

Financial instruments
The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in profit and loss.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Debtors
Basic financial assets, including trade and other debtors, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

Creditors
Basic financial liabilities, including trade and other creditors, loans from third parties and loans from related parties, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Such instruments are subsequently carried at amortised cost using effective interest method, less any impairment.

Cash and cash equivalents
Cash and cash equivalents are represented by cash in hand, deposits held at call with financial institutions, and other short-term highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amount of cash with insignificant risk of change in value.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 27 (2023 - 27 ) .

ESSEX INJECTION MOULDINGS
LIMITED (REGISTERED NUMBER: 02137067)

Notes to the Financial Statements - continued
for the year ended 30th November 2024


4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST OR VALUATION
At 1st December 2023
and 30th November 2024 1,337,150
DEPRECIATION
At 1st December 2023 1,117,172
Charge for year 12,824
At 30th November 2024 1,129,996
NET BOOK VALUE
At 30th November 2024 207,154
At 30th November 2023 219,978

Plant and machinery were valued on an open market basis on 30th November 2024 by the directors of the company.

Cost or valuation at 30th November 2024 is represented by:

Plant and
machinery
etc
£   
Valuation in 2016 140,330
Cost 1,196,820
1,337,150

Plant and machinery includes assets which were revalued during the year ended 30th November 2016. If these assets were held at historic cost they would have a carrying value of £54,320 (2023: £64,048) at the balance sheet date.

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 149,262 233,197
Amounts owed by group undertakings 500,000 500,000
Other debtors 15,324 18,063
664,586 751,260

ESSEX INJECTION MOULDINGS
LIMITED (REGISTERED NUMBER: 02137067)

Notes to the Financial Statements - continued
for the year ended 30th November 2024


6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts 10,126 10,000
Hire purchase contracts (see note 8) 37,594 32,872
Trade creditors 232,403 296,168
Taxation and social security 131,118 145,449
Other creditors 26,211 33,870
437,452 518,359

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Bank loans 13,502 22,842
Hire purchase contracts (see note 8) 61,340 98,934
Other creditors 50,000 50,000
124,842 171,776

8. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Hire purchase contracts
2024 2023
£    £   
Net obligations repayable:
Within one year 37,594 32,872
Between one and five years 61,340 98,934
98,934 131,806

Non-cancellable operating leases
2024 2023
£    £   
Within one year 42,358 47,775
Between one and five years 28,942 71,300
71,300 119,075

ESSEX INJECTION MOULDINGS
LIMITED (REGISTERED NUMBER: 02137067)

Notes to the Financial Statements - continued
for the year ended 30th November 2024


9. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£    £   
Bank loans 23,628 32,842
Factoring account 75,520 141,244
Hire purchase 98,934 131,806
198,082 305,892

The bank loan, overdraft and factoring account facilities, the latter of which is included within trade creditors, are secured by a fixed and floating charge over the company's assets and undertakings and by a personal guarantee from the four directors totalling £140,000 collectively.

The Company has a further bank loan which is secured by the Bounce Back Loan Scheme. This was provided by the Government during the Coronavirus pandemic.

The hire purchase creditor is secured against the asset to which it relates.

10. RESERVES
Revaluation
reserve
£   
At 1st December 2023 120,222
Deferred tax 287
Transfer between reserves (1,506 )

At 30th November 2024 119,003

11. RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

At the balance sheet date there were directors' current account balances totalling £50,000 (2023: £50,000).